In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
12 CRA consultants named top IP professionals in the 2021 IAM Patent 1000
12 CRA consultants were recognized as leading patent professionals by Intellectual Asset Management (IAM). The IAM Patent 1000 names the best-in-class patent...